Jay Short, PhD - World Medical Innovation Forum
WMIF Main Site
Jay Short
This speaker appears at this event:

Jay Short, PhD

Chairman, CEO, Cofounder, BioAlta, Inc.

Dr. Jay M. Short is Chairman, CEO and cofounder of BioAtla, Inc. (Nasdaq: BCAB) and is coinventor of BioAtla’s proprietary Conditionally Active Biologics (CAB) utilizing Protein-associated Chemical Switches (PaCS) therapeutic platform. BioAtla is a P2 clinical stage cancer therapeutics company with headquarters in San Diego and operations in Beijing. He is also Chairman and cofounder of Himalaya Therapeutics, SECZ leading development of CAB based therapeutics in Asia. He is founder and former Pres. of the E.O. Wilson Biodiversity Foundation and prior to this, was a founder of Diversa Corp. (now BASF), a pioneer in protein discovery and evolution from microbial biodiversity, where he served as CEO, Pres. and CTO and led the company in achieving the largest biotech IPO. Dr. Short also served as Pres. of Stratacyte, an antibody engineering company, and VP R&D and Operations for Stratagene (now Agilent) a leading research supply company. He earned his PhD in Biochemistry at CWRU and his BA in chemistry with honors at Taylor Univ.
Dr. Short is the recipient of two first place awards from UCSD- Connect Innovative Product Program, including for the development of the first combinatorial antibody discovery library (while at Stratagene and in collaboration with Scripps Clinic) and for the development of a key OECD approved transgenic genotoxicity testing models (Big Blue). He has authored more than 100 peer-reviewed publications and is named inventor of over 500 issued patents and several hundred pending patents. His patents ranked in the top ten based on citation frequency on the 2003 and 2004 Patent Scorecard by MIT Survey across all industries. In addition, he has served on the NRC panel for Chemical Science and Technology at NIST. In 2003 he received the ABL Innovations in HealthCare Gold award, and in 2004 he received the Henry F. Whalen, Jr. Award for Business Development by ACS. In 2006 Dr. Short was shortlisted by the editors of Nature Biotechnology as a personality making the most significant contribution to biotech in the past decade. In 2010 he received an International Best-of-the-Best award from YPO, as well as numerous other awards for leadership and innovation. Dr. Short also serves as director, advisor and consultant for a number of leading corporations and institutions.

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA